29/09/2026 – AB Science today announces a revision of its operating plan and financial calendar following a “for cause” sponsor Good Clinical Practice (GCP) inspection Download PDF Post navigationPreviousPrevious post:AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026Related PostsAB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026AB Science announces the successful completion of a EUR 2.3 million private placement1 July 2026AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML29 June 2026
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026
AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML29 June 2026
